Manuel Perez, MD
Urology · Hardeeville, SCNPI 1083627814
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,278 of the $8,684 with a category attached, or 60.8%. 38 manufacturers reported payments, led by Axonics, Inc. at 27.4% of the total. Reporting peaked in 2023 at $2,955 and has fallen 79.6% since, to $603 in 2025.
Across 188 payments — averaging $46.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Teleflex LLC$2K
- Neotract Inc.$1K
- AbbVie$267
- Procept Biorobotics Corporation$234
- Bayer$212
- plus $2K from 32 others
What the payments were for
- Travel & lodging$3,36739%
- Food & beverage$5,27861%
- Education$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 29 | $2,381 |
| Teleflex LLC | 23 | $2,155 |
| Neotract Inc. | 14 | $1,258 |
| AbbVie(2 entities) | 14 | $267 |
| Procept Biorobotics Corporation | 3 | $234 |
| Bayer | 9 | $212 |
| Astellas Pharma US Inc | 10 | $210 |
| Boston Scientific | 9 | $207 |
| Myovant Sciences Inc. | 7 | $203 |
| Kowa Pharmaceuticals America, Inc. | 11 | $181 |
| Calyxo, Inc. | 2 | $127 |
| Accord Healthcare, Inc. | 5 | $122 |
| Pfizer | 6 | $113 |
| Merck | 5 | $94 |
| Sumitomo Pharma America, Inc. | 4 | $91 |
| Antares Pharma, Inc. | 4 | $86 |
| Coloplast | 4 | $81 |
| Angiodynamics, Inc. | 1 | $69 |
| Medtronic(2 entities) | 3 | $67 |
| Convatec Inc. | 2 | $64 |
| Tolmar, Inc. | 2 | $50 |
| Blue Earth Diagnostics | 2 | $41 |
| Urovant Sciences Inc | 2 | $39 |
| Johnson & Johnson | 2 | $38 |
| SRS Medical Systems, Inc. | 1 | $37 |
| Laborie Medical Technologies Corp. | 2 | $30 |
| Olympus America Inc. | 1 | $29 |
| Myriad Genetic Laboratories, Inc. | 1 | $26 |
| Telix Pharmaceuticals | 1 | $22 |
| 180 Medical, Inc. | 1 | $21 |
| Assertio Therapeutics, Inc. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Vertex | 1 | $17 |
| SNAP Diagnostics LLC | 1 | $16 |
| Amgen | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| Hollister Incorporated | 1 | $14 |
| Mckesson Patient Care Solutions Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$1,931
- Bulkamid$1,687
- UroLift System$1,398
- UroLift$1,069
- Barrigel$138
- AQUABEAM SYSTEM$125
- CVAC Aspiration System$100
How this compares
$8,684 in reported general payments places this provider in the 75th percentile of 196 urology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 23 | $329,927 |
| GemtesaVibegron | 145 | $147,965 |
| MyrbetriqMirabegron | 108 | $104,603 |
| Solifenacin Succinate | 388 | $20,502 |
| XyostedTestosterone Enanthate | 15 | $15,820 |
| Tamsulosin Hcl | 778 | $15,548 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 322 | $12,026 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 288 | $11,901 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 46 | $7,742 |
| Potassium Citrate ErPotassium Citrate | 35 | $4,590 |
| Finasteride | 278 | $4,138 |
| Trimethoprim | 51 | $3,982 |
| Cephalexin | 432 | $3,628 |
| Doxazosin Mesylate | 157 | $3,008 |
| Silodosin | 36 | $2,723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $210 | $434,531131 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $91 | $147,965145 claims |
| Antares Pharma, Inc.Xyosted | $86 | $15,82015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 196 urology providers in South Carolina.
Other urology in Hardeeville
- Neal ShoreMyrtle Beach$3.2M
- Manish PatelElgin$213K
- Sandip PrasadCharleston$177K
- Benjamin DropkinGreenville$65K
- Ian MarshallCharleston$60K
- Elizabeth BozemanFlorence$57K
- Thomas KeaneCharleston$52K
- Abhishek SrivastavaMyrtle Beach$41K
- William BogacheMyrtle Beach$41K
- Christopher BallantyneGreenville$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.